About Us
About Aurobindo
Vision / Mission
Milestones
R&D
Manufacturing
Management
Board of Directors
Our Presence
Our Business
APUSA
Europe
Growth Markets
ARV
Overview
Key facts about HIV/AIDS
Products
Global Partners
Gallery
Corporate Video
Apitoria (API)
Eugia (Speciality products)
Curateq (Biosimilars) / Peptide
Sustainability
ESG / Sustainability
ESG Profile
Sustainability Reports
BMW Reports
Social Accountability Standards
Social Compliance Certification
Sustainability of Social Accountability Standards
Human Rights Policy
Progressive Health and Safety Practices
Community Impact
Supply Chain Management
Supplier Code of Conduct
CSR
Aurobindo Pharma Foundation
CSR Policy
Annual Report
Gallery
Annual Action Plan
Impact Assessment Reports - CSR Projects
Access to Healthcare
PEPFAR program
Investors
Results, Reports & Presentations
Results Announcements
Annual Reports
Financials - Subsidiaries
Related Party Transactions
Shareholder Information
Shareholding Pattern
Buyback of shares
Share Performance
Financial Highlights
Notice of Board Meetings
General Meetings
Dividend Record
Scheme of Arrangements
Unpaid Dividend Account Details
Registrar and Share Transfer Agent
Contact Details for Investor Grievance Redressal
Corporate Governance
Board of Directors
Governance Policies
Code of Conduct
Code of Practices and Procedures for Fair Disclosure
Appointment and Resignation of Directors
Contact Details of KMPs
IR Contacts
Disclosures Under Regulation 46
Disclosures under Regulation 46 of the LODR
Media
Press Releases
Corporate Kit
Careers
Our Culture & Values
Life @ Aurobindo
Work with us / Oppurtunities
Contact Us
Investors
Commitment towards creating consistent
value for our shareholders
2024 - 25
2023 - 24
2022 - 23
2021 - 22
2020 - 21
2019 - 20
2018 - 19
2017 - 18
2016 - 17
2015 - 16
2014 - 15
2013 - 14
2012 - 13
2011 - 12
2010 - 11
2009 - 10
Earnings News Release
PR-Q3 FY 2024-25
PR-Q2 FY 2024-25
PR-Q1 FY 2024-25
Earnings Presentation
Earnings Presentation-Q3 FY 2024-25
Earnings Presentation-Q2 FY 2024-25
Earnings Presentation-Q1 FY 2024-25
Financial Results
Q3 UFR 2024-25
Q2-UFR-2024-25-Corrigendum in Consolidated UFR
Q2 – UFR 2024-25
Q1 – UFR 2024-25
Earnings Call Details
Q3FY2025
Q2FY25
Q1FY25
